Brand Name
Hycamtin
Generic Name
Topotecan
View Brand Information FDA approval date: November 30, 2010
Classification: Topoisomerase Inhibitor
Form: Injection, Capsule
What is Hycamtin (Topotecan)?
HYCAMTIN ® capsules are indicated for the treatment of relapsed small cell lung cancer in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy. HYCAMTIN capsules is a topoisomerase inhibitor indicated for treatment of patients with relapsed small cell lung cancer .
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment